Abstract
Small molecules targeting p53 represent an emerging group of potentially useful agents for the improvement of antitumor therapy. These modulators include agents that activate wild-type p53 or reactivate mutant p53 and inhibitors of p53 functions. Preclinical evidences support the interest of combination strategies with conventional antitumor agents.
Keywords: p53, nutlins, pifithrins, histone deacetylase inhibitors, ubiquitin ligase inhibitors, apoptosis, cancer cells, drug combination
Mini-Reviews in Medicinal Chemistry
Title: Small Molecules Targeting p53 to Improve Antitumor Therapy
Volume: 8 Issue: 9
Author(s): G. L. Beretta, L. Gatti, V. Benedetti, P. Perego and F. Zunino
Affiliation:
Keywords: p53, nutlins, pifithrins, histone deacetylase inhibitors, ubiquitin ligase inhibitors, apoptosis, cancer cells, drug combination
Abstract: Small molecules targeting p53 represent an emerging group of potentially useful agents for the improvement of antitumor therapy. These modulators include agents that activate wild-type p53 or reactivate mutant p53 and inhibitors of p53 functions. Preclinical evidences support the interest of combination strategies with conventional antitumor agents.
Export Options
About this article
Cite this article as:
Beretta L. G., Gatti L., Benedetti V., Perego P. and Zunino F., Small Molecules Targeting p53 to Improve Antitumor Therapy, Mini-Reviews in Medicinal Chemistry 2008; 8 (9) . https://dx.doi.org/10.2174/138955708785132774
DOI https://dx.doi.org/10.2174/138955708785132774 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmaceutical Applications of Graphene-based Nanosheets
Current Pharmaceutical Biotechnology Viral Based Gene Therapy for Prostate Cancer
Current Gene Therapy Imidazoles and Benzimidazoles as Tubulin-Modulators for Anti-Cancer Therapy
Current Medicinal Chemistry Meet Our Editorial Board Member
Letters in Drug Design & Discovery Protein Kinase C and Prostate Carcinogenesis: Targeting the Cell Cycle and Apoptotic Mechanisms
Current Drug Targets Drug Resistance and Apoptosis in Cancer Treatment: Development of New Apoptosis-Inducing Agents Active in Drug Resistant Malignancies
Current Medicinal Chemistry - Anti-Cancer Agents On the Future Development of Optimally-Sized Lipid-Insoluble Systemic Therapies for CNS Solid Tumors and Other Neuropathologies
Recent Patents on CNS Drug Discovery (Discontinued) Recent Clinical Trials of mTOR-Targeted Cancer Therapies
Reviews on Recent Clinical Trials Targeting the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Signaling Network in Cancer Stem Cells
Current Medicinal Chemistry Fluoxetine and all other SSRIs are 5-HT<sub>2B</sub> Agonists - Importance for their Therapeutic Effects
Current Neuropharmacology Dual-Specificity MAP Kinase Phosphatases as Targets of Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Natural Polyphenols in the Treatment of Alzheimer’s Disease
Current Drug Targets Expression of Rab3b in Human Glioma: Influence on Cell Proliferation and Apoptosis
Current Pharmaceutical Design Anti-Angiogenic Therapies for Children with Cancer
Current Cancer Drug Targets HLA-G Expression in Cancers: Potential Role in Diagnosis, Prognosis and Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Intracellular Delivery of Potential Therapeutic Genes: Prospects in Cancer Gene Therapy
Current Gene Therapy Histone Deacetylase Inhibitors in Cancer Therapy: New Compounds and Clinical Update of Benzamide-Type Agents
Current Topics in Medicinal Chemistry The Neurotachykinin NK1 Receptor – A Novel Target for Diagnostics and Therapy
Current Molecular Imaging (Discontinued) Potentials of ES Cell Therapy in Neurodegenerative Diseases
Current Pharmaceutical Design New Perspectives in Glioma Immunotherapy
Current Pharmaceutical Design